Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sipuleucel-T (Provenge) Clear all
Completed Phase 3 Interventional Results available

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

NCT00065442
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sipuleucel-T, APC-Placebo
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
65
States / cities
Laguna Hills, California • Loma Linda, California • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2010 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

NCT01807065
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Soft Tissue Metastases, Stage IV Prostate Cancer
Interventions
sipuleucel-T, external beam radiation therapy, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Duarte, California • Pasadena, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer

NCT03329742
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
Low protein diet, Control protein diet
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 28, 2026, 7:33 PM EDT
Recruiting Phase 2 Interventional

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

NCT06100705
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone Cypionate, Sipuleucel-T
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

NCT02463799
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, Sipuleucel-T
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

NCT01487863
View directory record Official record
Conditions
Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
Interventions
sipuleucel-T, abiraterone acetate
Biological · Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
21
States / cities
La Jolla, California • La Mesa, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer

NCT00901342
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
18
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Park Ridge, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 28, 2026, 7:33 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

NCT05751941
View directory record Official record
Conditions
Prostate Cancer, Metastatic Prostate Cancer
Interventions
Abiraterone, Enzalutamide, Apalutamide, Sipuleucel-T
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

NCT01804465
View directory record Official record
Conditions
Prostate Cancer
Interventions
SipT Treatment, Ipilimumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 28, 2026, 7:33 PM EDT
Completed No phase listed Observational

Immune Monitoring on Sipuleucel-T

NCT02237170
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Las Vegas, Nevada • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

NCT03686683
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
56
States / cities
Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 28, 2026, 7:33 PM EDT
Completed No phase listed Observational

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

NCT07477756
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005947
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T, Placebo
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
34
States / cities
Duarte, California • Loma Linda, California • Rancho Mirage, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2010 · Synced Sep 28, 2026, 7:33 PM EDT
Withdrawn Phase 2 Interventional

Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer

NCT02793219
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sipuleucel-T, Docetaxel
Biological · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

NCT01818986
View directory record Official record
Conditions
Metastatic Castrate-resistant Prostate Cancer, mCRPC
Interventions
Sipuleucel-T, Stereotactic Ablative Body Radiation
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 28, 2026, 7:33 PM EDT
Active, not recruiting Phase 1 Interventional

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

NCT05806814
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
Sipuleucel-T
Biological
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

NCT02036918
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sipuleucel-T, Lymph Node Biopsy
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 28, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

NCT01706458
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T, DNA Vaccine
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 28, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer

NCT01338012
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Laguna Hills, California • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 28, 2026, 7:33 PM EDT